PLAT and hematoma: The MISTIE III trial, a global multi-center randomized controlled trial (RCT), found that after catheter aspiration combined with recombinant tissue plasminogen activator (rt-PA), when the residual hematoma volume was≤15 ml, the prognosis of neurological function [modified Rankin scale (mRS≤3)] at 1 year after surgery was better than that of conservative medical treatment (3), while the accuracy of catheter placement significantly affected the hematoma clearance and prognosis.